Clinically meaningful ORR across organs with Jakafi® (ruxolitinib)1,2

REACH1: Day 28 responses were achieved in the majority of patients treated with Jakafi and were seen across organs1,2

REACH1: ORR at Day 28 (Primary Endpoint)1,a
REACH1 primary endpoint: ORR at Day 28 bar chart

aDefined as the proportion of patients who had a CR, PR, or VGPR at day 28 based on CIBMTR definitions.1

REACH1: ORR at Day 28 by Organ (Subgroup Analysis)1,2
REACH1 subgroup analysis of ORR at Day 28 by organ chart

Study design

Jakafi was approved by the FDA for SR aGVHD based on positive results from the REACH1 study2

REACH1 Study Design1,3

REACH2 Study Design4

Phase 2 studya

REACH1 and REACH2 Study designs

Phase 3 studyc


REACH2 data are not included in the Jakafi Prescribing Information.

  • aPatients had grade 2 to 4 aGVHD, as defined according to MAGIC criteria, that occurred after allogeneic hematopoietic stem cell transplantation.1
  • b22 patients were not included in the efficacy analysis because they received 2 or more prior anti-GVHD therapies (n=12) or did not receive an adequate dose of corticosteroids (n=10). All 71 patients were included in the safety analysis.1,3
  • cThe REACH2 study was conducted in 105 centers across 22 countries.4
  • dCrossover from control therapy to Jakafi therapy was permitted if patients did not have a response at day 28 or if they had a loss of response thereafter and received additional systemic therapy, and they did not have signs of chronic GVHD.4
  • eControl therapy was chosen by the investigator at the time of randomization (antithymocyte globulin, extracorporeal photopheresis, mesenchymal stromal cells, low-dose methotrexate, mycophenolate mofetil, everolimus, sirolimus, etanercept, or infliximab).4

Definition of SR aGVHD in the REACH studies3,4

In both studies, SR aGVHD was defined as disease progression after 3 days of high-dose systemic steroid treatment, lack of improvement after 7 days of such treatment, or failure to successfully taper steroid

  • REACH1 also specified patients as steroid refractory if they began low-dose steroids for skin or skin plus upper GI GVHD and developed GVHD in a new organ
  • Failure to taper was defined in REACH1 as the inability to achieve a 50% taper of steroid dose, and in REACH2 as the need to increase to ≥2 mg/kg/day methylprednisolone or inability to taper below 0.5 mg/kg/day for at least 7 days

aGVHD=acute graft-versus-host disease; BID=twice daily; GI=gastrointestinal; MAGIC=Mount Sinai Acute GVHD International Consortium; ORR=overall response rate; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid-refractory.

The REACH Studies in Steroid-Refractory aGVHD: Overall Response Rate, Including by Grade and Organ

Oncologist Dr Michael Bishop reviews the primary efficacy data and safety profile from the REACH1 and REACH2 clinical studies evaluating Jakafi in patients with SR aGVHD.


aGVHD=acute graft-versus-host disease; CI=confidence interval; CIBMTR=Center for International Blood and Marrow Transplant Research; CR=complete response; GI=gastrointestinal; ORR=overall response rate; PR=partial response; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid-refractory; VGPR=very good partial response.

References: 1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 2. Data on file. Incyte Corporation. Wilmington, DE. 3. Jagasia M, Perales MA, Schroeder MA, et al; for the REACH1 Study Group. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739-1749. Supplementary appendix available at: 4. Zeiser R, von Bubnoff N, Butler J, et al; for the REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810. Supplementary appendix available at: